Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

Eli Lilly's Obesity Pipeline Is Getting Crowded. That's Great News for Investors

Eli Lilly's pipeline could help it survive a slew of brand-new launches in the weight loss drug market.

The weight loss drug market is booming and expected to grow significantly in the coming years. One of the leading companies in this space is Eli Lilly (LLY), which has seen impressive financial results recently, largely due to its obesity franchise. Despite concerns about growing competition, Eli Lilly's pipeline appears robust enough to maintain its position as the top player in the anti-obesity space for the next five years.

Currently, Eli Lilly's approved weight loss portfolio consists of two products: Zepbound, an injectable tirzepatide, and Foundayo, an oral anti-obesity treatment. Zepbound, which was approved about three years ago, has been experiencing strong sales growth, with revenue increasing by 49% year over year in the third quarter to $5.4 billion. Foundayo, approved in April, has also shown promising commercial performance, generating $184 million in revenue during the same period.

While competitors may launch treatments that rival or surpass Zepbound and Foundayo in terms of efficacy, Eli Lilly is likely to respond in kind, potentially helping the company maintain or even improve its market share. Some of Eli Lilly's most promising pipeline candidates include retatrutide and EloraTZP, which have demonstrated greater weight loss than Zepbound.

However, this could lead to cannibalization of Zepbound sales, though it's preferable for Eli Lilly to capture these sales with its own products rather than allowing other pharmaceutical giants to take them away.

Eli Lilly's pipeline expansion could also help the company attract patients who haven't achieved sufficient weight loss with Zepbound alone. Retatrutide, which has already been made available to some patients despite not being fully approved, is intended for those who have failed to respond to standard obesity treatments. Eloralintide, on the other hand, is not a GLP-1 product but mimics the amylin hormone, offering a differentiated approach with comparable weight-loss efficacy to GLP-1 products and strong tolerability.

Moreover, Eli Lilly's growing portfolio could help the company maintain strong pricing power as more weight-loss options enter the market. Treatments with superior efficacy could potentially command a premium price, allowing the company to sustain fast revenue growth while preserving margins and profits.

Despite the increasing competition in the weight-loss market, Eli Lilly's pipeline indicates that the company could still perform well. The company's revenue and earnings have outpaced industry averages in recent years, and its growth rate is likely to slow down eventually. However, given its strong performance in the weight loss market and progress in other areas such as diabetes, oncology, immunology, and neuroscience, an estimated 20% to 25% annual earnings per share (EPS) growth rate over the next five years seems reasonable.

Consequently, Eli Lilly's forward price-to-earnings ratio of 27.2 may not be unreasonable, even though it is higher than the average for healthcare stocks (18.9). Therefore, the stock could be a buy, as indicated by The Motley Fool's Stock Advisor team, which recommends the company based on its impressive track record.

Rewritten by urgent.news; may contain errors — check the original.

Source: fool.com

Read the original at fool.com →

Report a problem with this story

More in Health & Medicine

More from Sunday 22 November →